肝疾患診断薬市場：製品別、疾患タイプ別、エンドユーザー別-2025-2030年の世界予測

肝疾患診断薬市場は、2024年には110億9,000万米ドルとなり、2025年には125億7,000万米ドル、CAGR12.99%で成長し、2030年には230億8,000万米ドルに達すると予測されています。

急速に進化する肝疾患診断の領域では、技術革新と精度がこれまで以上に重要です。本レポートでは、肝疾患の診断と管理方法を変革するシフトについて深く掘り下げています。本レポートではまず、より正確で信頼性が高く、侵襲性の低い診断方法へと業界を進化させる市場力学を明確に説明します。主な促進要因としては、技術の進歩、臨床手法の継続的な改良、早期発見と個別化治療計画への需要の高まりなどが挙げられます。

本分析では全体的な視野に立ち、市場動向に影響を与える最新動向、新たな課題、画期的な開発を体系的に探求しています。肝疾患は世界的に重大な健康上の課題であり、診断プロトコルの強化は重篤な転帰を軽減し、患者のケアを最適化する上で極めて重要です。この包括的なイントロダクションは、様々なセグメンテーション考察、地域分析、競合情勢、実行可能な推奨事項など、意思決定者や業界専門家に新たなビジネスチャンスや戦略的必須事項を伝えるために作成された後続のセクションの舞台を整えます。

肝疾患診断薬市場の変革

近年、急速な技術進歩や臨床アプローチの進化により、肝疾患診断の状況は大きく変化しています。画像診断や低侵襲手技の大幅な革新により、肝疾患の検出方法は大きく変わりました。バイオマーカーの開発や人工知能と画像診断の融合がますます重視されるようになり、診断の精度とスピードの向上には欠かせないものとなっています。かつては従来の画像診断に大きく依存していた調査手法も、現在では最先端の血液検査や高度な内視鏡検査によって補完されるようになっています。

臨床が進化するにつれて、新しい生検技術の採用は患者の安全性と診断の信頼性の両方を向上させています。この進化は、プロセスの合理化と処置時間の短縮が高く評価される早期発見に対する需要の高まりへの対応でもあります。デジタルヘルス・ソリューションと従来の診断手法との相乗効果により、シームレスな患者体験が可能となり、医療提供者は経過観察や疾患進行の監視が容易になります。

こうした変革的動向は、臨床ワークフローを再構築するだけでなく、ヘルスケア利害関係者の広範な戦略にも影響を及ぼしています。業界関係者は、このような変化の状況を受け入れることで、カスタマイズ可能で患者固有のニーズに対応できる統合診断ソリューションを提供し、最終的に臨床転帰を向上させることができます。

肝疾患診断における主要なセグメンテーションインサイト

肝疾患診断薬市場を理解する上で、重要なセグメンテーションの洞察がバックボーンを形成しています。最初のセグメンテーションは、多様な診断方法によって市場を細分化することです。生検技術の領域では、腹腔鏡、経皮、経静脈の各アプローチを調査し、それぞれ侵襲性と診断精度のバランスをとるように工夫されています。同様に血液ベースの検査では、アラニントランスアミナーゼ、アスパラギン酸トランスアミナーゼ、ガンマ-グルタミルトランスペプチダーゼ検査など、さまざまな酵素評価に焦点を当て、肝機能と肝障害に関する微妙な洞察を提供しています。一方、画像診断については、CTスキャン、MRI、超音波検査など、さまざまな精度のモダリティを掘り下げて評価します。

2つ目のセグメンテーションでは、急性肝炎やアルコール性肝疾患から慢性肝炎、肝硬変、肝細胞がん、非アルコール性脂肪性肝疾患に至るまで、疾患の種類を把握します。この次元分析により、それぞれの肝疾患の診断上の課題や必要なリソースを確実に把握することができます。最後に、エンドユーザーに基づくセグメンテーションでは、診断研究所、病院、研究機関における診断技術の多様な展開を検証します。各セグメンテーションは、臨床および業務ダイナミクスを明らかにするだけでなく、異なる市場垂直方向における技術展開とビジネス成長の機会も明らかにします。

これらの市場セグメンテーションの洞察により、利害関係者は、市場内の特定のニッチをターゲットとし、製品ポートフォリオを改良し、肝臓関連疾患のスペクトル全体にわたる独自の診断課題に対処するための戦略的イニシアチブを調整するために必要な明確さを得ることができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 肝臓診断の必要性が高まっている認識と早期診断の取り組み
    • ヘルスケア費の増加は肝疾患診断サービスへの投資増加に貢献している
    • 世界中で肝疾患の罹患率が上昇しており、診断の需要が高まっています。
  • 抑制要因
    • 高度な診断手順の高コスト
  • 機会
    • より正確で侵襲性の低い診断方法の開発に貢献する技術の進歩
    • 遠隔肝疾患モニタリングおよび診断のための遠隔医療ソリューションへの関心の高まり
  • 課題
    • 新しい診断ツールに対するより厳しい規制と長い承認プロセス
• 市場セグメンテーション分析
  • 提供：食道静脈瘤の検出と管理における内視鏡検査の重要性の高まり
  • エンドユーザー：病院では即時の検査と介入戦略を提供するために肝疾患診断薬の採用が拡大しています
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 肝疾患診断薬市場：提供別

• 生検技術
  • 腹腔鏡下肝生検
  • 経皮肝生検
  • 経静脈肝生検
• 血液検査
  • アラニントランスアミナーゼ検査
  • アスパラギン酸トランスアミナーゼ検査
  • ガンマ-グルタミルトランスペプチダーゼ検査
• 内視鏡検査
• 画像診断
  • CTスキャン
  • MRI
  • 超音波

第7章 肝疾患診断薬市場：疾患タイプ別

• 急性肝炎
• アルコール性肝疾患
• 慢性肝炎
• 肝硬変
• 肝細胞がん
• 非アルコール性脂肪性肝疾患

第8章 肝疾患診断薬市場：エンドユーザー別

• 診断検査室
• 病院
• 調査機関

第9章 南北アメリカの肝疾患診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の肝疾患診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの肝疾患診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Amgen Inc.
• Argon Medical Devices, Inc.
• Bayer AG
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• BioMerieux SA
• Boston Scientific Corporation
• Cook Medical Incorporated
• Epigenomics AG
• F. Hoffmann-La Roche Ltd.
• Fujifilm Holdings Corporation
• Hepatiq, Inc.
• Hologic, Inc.
• Horiba, Ltd.
• Koninklijke Philips N.V.
• Laboratory Corporation of America Holdings
• Medtronic PLC
• Merck & Co., Inc.
• Perspectum Ltd.
• Quest Diagnostics Incorporated
• Randox Laboratories Ltd.
• Ri.Mos. Srl
• Siemens Healthineers AG
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. LIVER DISEASE DIAGNOSTICS MARKET MULTI-CURRENCY
• FIGURE 2. LIVER DISEASE DIAGNOSTICS MARKET MULTI-LANGUAGE
• FIGURE 3. LIVER DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 4. LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 15. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 17. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. LIVER DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 23. LIVER DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. LIVER DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. LIVER DISEASE DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY LAPAROSCOPIC LIVER BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY PERCUTANEOUS LIVER BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY TRANSVENOUS LIVER BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALANINE TRANSAMINASE TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ASPARTATE TRANSAMINASE TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY GAMMA-GLUTAMYL TRANSPEPTIDASE TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOSCOPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ACUTE HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CHRONIC HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY CIRRHOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY NON-ALCOHOLIC FATTY LIVER DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 55. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 56. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 57. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 58. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CANADA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 87. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 88. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 89. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 90. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 91. CHINA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 93. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 94. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 95. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 96. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 97. INDIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 103. INDONESIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TAIWAN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 145. THAILAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 151. VIETNAM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 164. DENMARK LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 170. EGYPT LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 176. FINLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 182. FRANCE LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 188. GERMANY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 194. ISRAEL LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 195. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 196. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 197. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 198. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 199. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 200. ITALY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 206. NETHERLANDS LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 212. NIGERIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 218. NORWAY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 220. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 221. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 222. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 223. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 224. POLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 225. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 226. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 227. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 228. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 229. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 230. QATAR LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 236. RUSSIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 242. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 254. SPAIN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 260. SWEDEN LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 266. SWITZERLAND LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 272. TURKEY LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BIOPSY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY BLOOD-BASED TESTS, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 284. UNITED KINGDOM LIVER DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 285. LIVER DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 286. LIVER DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

The Liver Disease Diagnostics Market was valued at USD 11.09 billion in 2024 and is projected to grow to USD 12.57 billion in 2025, with a CAGR of 12.99%, reaching USD 23.08 billion by 2030.

In the rapidly evolving realm of liver disease diagnostics, innovation and precision are more critical than ever. This report offers a deep dive into the transformative shifts reshaping how liver disorders are diagnosed and managed. The discussion begins with a clear articulation of prevailing market dynamics that are steering industry evolution towards more accurate, reliable, and less invasive diagnostic procedures. Key drivers include advances in technology, a continuous refinement in clinical practices, and the growing demand for early-stage detection coupled with personalized treatment plans.

The analysis takes a holistic view, systematically exploring the latest trends, emerging challenges, and breakthrough developments influencing market behavior. With liver disease presenting a significant health challenge globally, enhanced diagnostic protocols are critical in mitigating severe outcomes and optimizing patient care. This comprehensive introduction sets the stage for the subsequent sections that navigate through various segmentation insights, regional analyses, the competitive landscape, and actionable recommendations, all crafted to inform decision-makers and industry experts on emerging opportunities and strategic imperatives.

Transformative Shifts in the Liver Disease Diagnostics Landscape

Recent years have witnessed transformative shifts across the liver disease diagnostics landscape, driven by rapid technological advancements and evolving clinical approaches. Significant innovations in imaging modalities and minimally invasive procedures have revolutionized detection methods. There is an increasing emphasis on developing biomarkers and integrating artificial intelligence with diagnostic imaging, which has been critical in enhancing the accuracy and speed of diagnoses. Methodologies that once relied heavily on traditional imaging are now being complemented by state-of-the-art blood-based tests and sophisticated endoscopic procedures.

As clinical practices evolve, the adoption of novel biopsy techniques has improved both patient safety and diagnostic reliability. This evolution is also a response to the escalating demand for early detection, where streamlined processes and reduced procedure times are highly valued. The synergy between digital health solutions and traditional diagnostic methods enables a seamless patient experience, making it easier for health care providers to conduct follow-ups and monitor disease progression.

These transformative trends are not only reshaping clinical workflows but also influencing the broader strategies of healthcare stakeholders. By embracing this landscape of change, industry participants are better positioned to deliver integrated diagnostic solutions that are customizable and responsive to patient-specific needs, ultimately driving enhanced clinical outcomes.

Key Segmentation Insights in Liver Disease Diagnostics

Critical segmentation insights form the backbone of understanding the liver disease diagnostics market. The first segmentation focuses on offerings, segmenting the market through diverse diagnostic methods. In the realm of biopsy techniques, the investigation spans laparoscopic, percutaneous, and transvenous approaches, each crafted to balance invasiveness with diagnostic accuracy. Similarly, blood-based tests are dissected by focusing on different enzyme assessments that include alanine transaminase, aspartate transaminase, and gamma-glutamyl transpeptidase tests, providing nuanced insights into liver function and damage. Meanwhile, imaging diagnostics are evaluated by delving into modalities such as CT scans, MRI, and ultrasound, which offer varying levels of precision and are integral in both acute and chronic assessments.

The second segmentation captures disease types, ranging from acute hepatitis and alcoholic liver disease to chronic hepatitis, cirrhosis, hepatocellular carcinoma, and non-alcoholic fatty liver disease. This dimensional analysis ensures that each liver condition is explored in terms of its unique diagnostic challenges and resource requirements. Lastly, segmentation based on end-users provides an examination of the varied deployment of diagnostic technologies across diagnostic laboratories, hospitals, and research institutes. Each segment not only highlights distinct clinical and operational dynamics but also reveals tailored opportunities for technology deployment and business growth in different market verticals.

These segmentation insights collectively empower stakeholders with the clarity needed to target specific niches within the market, refine product portfolios, and align strategic initiatives to address unique diagnostic challenges across the spectrum of liver-related diseases.

Based on Offering, market is studied across Biopsy Techniques, Blood-Based Tests, Endoscopy, and Imaging Diagnostics. The Biopsy Techniques is further studied across Laparoscopic Liver Biopsy, Percutaneous Liver Biopsy, and Transvenous Liver Biopsy. The Blood-Based Tests is further studied across Alanine Transaminase Test, Aspartate Transaminase Test, and Gamma-Glutamyl Transpeptidase Test. The Imaging Diagnostics is further studied across CT Scan, MRI, and Ultrasound.

Based on Disease Type, market is studied across Acute Hepatitis, Alcoholic Liver Disease, Chronic Hepatitis, Cirrhosis, Hepatocellular Carcinoma, and Non-Alcoholic Fatty Liver Disease.

Based on End-User, market is studied across Diagnostic Laboratories, Hospitals, and Research Institutes.

Assessing Regional Variations in Liver Disease Diagnostics

A regional assessment of the liver disease diagnostics market reveals significant geographic variations that influence market dynamics and growth trajectories. In the Americas, robust healthcare infrastructures and a pronounced focus on early disease detection have paved the way for the adoption of advanced diagnostic modalities. The region also benefits from extensive research and development investments, driving innovations that are rapidly integrated into clinical practices.

Across Europe, the Middle East, and Africa, diverse healthcare systems and regulatory frameworks have resulted in a dynamic, albeit fragmented, market landscape. Here, the interplay of governmental policies, reimbursement strategies, and regional disease prevalence creates both challenges and opportunities for diagnostic technology manufacturers. In these regions, collaborations between public and private healthcare providers are instrumental in facilitating the diffusion of diagnostic innovations.

The Asia-Pacific region presents a contrast, characterized by burgeoning healthcare markets, a large patient pool, and an increasing prevalence of lifestyle-related liver conditions. The region's rapid economic development and shifting disease patterns are compelling market players to adapt their strategies to meet the rising demand for cutting-edge diagnostic services. An increased focus on healthcare accessibility, combined with ongoing investments in medical technology facilities, is gradually transforming the diagnostic landscape in Asia-Pacific into one of the most vibrant and competitive globally.

These regional insights underscore the importance of tailored marketing strategies and localized product development to effectively respond to unique regional dynamics and optimize market penetration.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Leading Companies in Liver Disease Diagnostics

The competitive landscape in liver disease diagnostics is marked by robust innovation and strategic maneuvering by key market players. Leading companies have distinguishably played catalytic roles in shaping this market by deploying state-of-the-art diagnostic solutions and continuously refining their product portfolios. Prominent industry players such as Abbott Laboratories, Amgen Inc., and Argon Medical Devices, Inc. are at the forefront, leveraging expansive research networks and advanced technologies to secure competitive advantages.

Other influential companies include Bayer AG, Becton, Dickinson and Company, and Bio-Rad Laboratories, Inc. Their strategic focus on integrating diagnostic tests with streamlined clinical procedures has significantly reduced the turnaround time in diagnosing liver conditions. BioMerieux SA, Boston Scientific Corporation, and Cook Medical Incorporated have also cemented their positions through continuous innovation, backed by extensive clinical validation studies and rigorous R&D initiatives.

The market has further been invigorated by the contributions of Epigenomics AG and F. Hoffmann-La Roche Ltd., whose efforts in precision diagnostics are well recognized. Companies such as Fujifilm Holdings Corporation, Hepatiq, Inc., and Hologic, Inc. continue to expand their technological capabilities by forging strategic partnerships and investing in next-generation diagnostic platforms. Horiba, Ltd., Koninklijke Philips N.V., and Laboratory Corporation of America Holdings have demonstrated a consistent trajectory of growth by focusing on market-specific demands that encompass both chronic and acute liver disease diagnostics.

Recognized leaders in the field such as Medtronic PLC, Merck & Co., Inc., Perspectum Ltd., Quest Diagnostics Incorporated, and Randox Laboratories Ltd. further underscore the market's competitive intensity. Companies including Ri.Mos. Srl, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc. finalize this comprehensive roster of industry trailblazers, each contributing significantly to the evolution of diagnostic procedures with their dynamic range of product offerings and pioneering solutions in the liver disease diagnostics arena.

The report delves into recent significant developments in the Liver Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amgen Inc., Argon Medical Devices, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux SA, Boston Scientific Corporation, Cook Medical Incorporated, Epigenomics AG, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Hepatiq, Inc., Hologic, Inc., Horiba, Ltd., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Medtronic PLC, Merck & Co., Inc., Perspectum Ltd., Quest Diagnostics Incorporated, Randox Laboratories Ltd., Ri.Mos. Srl, Siemens Healthineers AG, and Thermo Fisher Scientific, Inc.. Strategic Recommendations for Industry Leaders

For industry leaders looking to navigate the dynamic and competitive landscape of liver disease diagnostics, several strategic recommendations can be drawn from emerging trends and market insights. Leaders are encouraged to focus on research and development initiatives that prioritize precision and minimally invasive diagnostic techniques. Investing in technologies that synergistically combine imaging modalities, blood-based tests, and biopsy techniques can significantly enhance diagnostic accuracy and improve patient outcomes.

Another key recommendation is to cultivate robust partnerships with research institutes and hospitals. This collaborative approach not only broadens the scope of clinical trials but also accelerates the adoption of new diagnostic methods. Aligning product innovation with regional market needs, particularly in rapidly growing areas like Asia-Pacific, ensures that solutions are both relevant and timely.

Industry players should also consider diversifying their product offerings to address the multifaceted nature of liver diseases. The market calls for an integrated approach that spans from acute to chronic conditions, and offering segmented solutions for different disease types is imperative. Furthermore, maintaining transparency around clinical efficacy and regulatory compliance will strengthen stakeholder trust and drive market acceptance.

Finally, leveraging digital health platforms to streamline patient data and integrate real-time analytics will empower stakeholders with actionable insights, thereby fostering a proactive rather than reactive approach in disease management. These recommendations collectively form a blueprint aimed at sustaining competitive advantage and fostering long-term growth in the liver disease diagnostics market.

Conclusion: Shaping the Future of Liver Disease Diagnostics

In conclusion, the liver disease diagnostics market stands at a pivotal juncture, characterized by significant technological advancements, evolving segmentation insights, and diverse regional dynamics. The comprehensive examination of offering-based segmentation, disease-specific demands, and end-user needs reveals a market that is both complex and ripe with opportunity. Embracing transformative shifts, such as the integration of digital health tools and the adoption of advanced diagnostic techniques, has set the foundation for enhanced clinical outcomes.

The competitive landscape, driven by innovation from top companies, underscores the importance of continuous improvement and strategic agility. By aligning product development with evolving patient needs and regulatory environments, industry leaders can effectively address the challenges inherent in diagnosing liver diseases and drive superior value for healthcare providers and patients alike.

Taken together, the insights and data presented in this report provide a nuanced understanding of the current and future trends in liver disease diagnostics. The path ahead is filled with both challenges and opportunities that, when navigated effectively, can lead to groundbreaking advancements and improved healthcare outcomes across the globe.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing awareness and early diagnosis initiatives expanding the need for liver diagnostics
    • 5.1.1.2. Rising healthcare expenditure contributing to improved investment in liver disease diagnostic services
    • 5.1.1.3. Rising prevalence of liver diseases globally which is increasing the demand for diagnostics
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of advanced diagnostic procedures
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements contributing to the development of more precise and less invasive diagnostic methods
    • 5.1.3.2. Growing interest in telehealth solutions for remote liver disease monitoring and diagnostics
  • 5.1.4. Challenges
    • 5.1.4.1. Stricter regulations and lengthy approval process for new diagnostic tools
• 5.2. Market Segmentation Analysis
  • 5.2.1. Offering: Rising significance of endoscopy for detecting and managing esophageal varices
  • 5.2.2. End-User: Growing adoption of liver disease diagnostics in hospitals to offer immediate testing and intervention strategies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Liver Disease Diagnostics Market, by Offering

• 6.1. Introduction
• 6.2. Biopsy Techniques
  • 6.2.1. Laparoscopic Liver Biopsy
  • 6.2.2. Percutaneous Liver Biopsy
  • 6.2.3. Transvenous Liver Biopsy
• 6.3. Blood-Based Tests
  • 6.3.1. Alanine Transaminase Test
  • 6.3.2. Aspartate Transaminase Test
  • 6.3.3. Gamma-Glutamyl Transpeptidase Test
• 6.4. Endoscopy
• 6.5. Imaging Diagnostics
  • 6.5.1. CT Scan
  • 6.5.2. MRI
  • 6.5.3. Ultrasound

7. Liver Disease Diagnostics Market, by Disease Type

• 7.1. Introduction
• 7.2. Acute Hepatitis
• 7.3. Alcoholic Liver Disease
• 7.4. Chronic Hepatitis
• 7.5. Cirrhosis
• 7.6. Hepatocellular Carcinoma
• 7.7. Non-Alcoholic Fatty Liver Disease

8. Liver Disease Diagnostics Market, by End-User

• 8.1. Introduction
• 8.2. Diagnostic Laboratories
• 8.3. Hospitals
• 8.4. Research Institutes

9. Americas Liver Disease Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Liver Disease Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Liver Disease Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. FPNV Positioning Matrix, 2024
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Argon Medical expands liver diagnostics portfolio with innovative device launches
  • 12.3.2. Apollo hospitals unveils advanced fatty liver clinic with innovative diagnostic and treatment solutions
  • 12.3.3. Quibim unveils QP-liver for enhanced AI-driven diagnosis of diffuse liver diseases
  • 12.3.4. E-Scopics Announces Commercial Launch Of Hepatoscope in the Us And Opens its Subsidiary in the US
  • 12.3.5. Stone Diagnostics to Provide Fibronostics Liver Disease Test
  • 12.3.6. Predictive Health Intelligence Launches Tool For Undiagnosed Liver Disease
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Amgen Inc.
• 3. Argon Medical Devices, Inc.
• 4. Bayer AG
• 5. Becton, Dickinson and Company
• 6. Bio-Rad Laboratories, Inc.
• 7. BioMerieux SA
• 8. Boston Scientific Corporation
• 9. Cook Medical Incorporated
• 10. Epigenomics AG
• 11. F. Hoffmann-La Roche Ltd.
• 12. Fujifilm Holdings Corporation
• 13. Hepatiq, Inc.
• 14. Hologic, Inc.
• 15. Horiba, Ltd.
• 16. Koninklijke Philips N.V.
• 17. Laboratory Corporation of America Holdings
• 18. Medtronic PLC
• 19. Merck & Co., Inc.
• 20. Perspectum Ltd.
• 21. Quest Diagnostics Incorporated
• 22. Randox Laboratories Ltd.
• 23. Ri.Mos. Srl
• 24. Siemens Healthineers AG
• 25. Thermo Fisher Scientific, Inc.